Syed Raza

Awali Hospital, Bahrain

Title: Underuse and Misuse of Newer Antidiabetic Medications with Established Positive Cardiovascular Outcome.

---

Biography

Dr Syed  Raza  graduated from Aligarh University in India  in 1993. After completing his postgraduate degree in Medicine from the same university, he moved to the UK for higher specialist studies. He successfully completed MRCP and CCT and later also  awarded Fellow of the Royal College of Physicians of Edinburgh. He was awarded professor John Goodwin prize for outstanding performance in Diploma Cardiology exam  at Hammersmith Hospital, University of London in 2001.  Dr  Raza  is  Fellow  of  American  College  of  Cardiology  ,  American  College  of  Chest  Physicoans  as  well  as  Fellow  of  European  Society  of  Cardiology.  He  is  also  on  the  committee  of  Acute  Cardiovascular  Care.  Heart  Failure  and  Cardiovascular  Imaging (  European  Society of  Cardiology )

He is currently serving as  consultant in Cardiology and Head of the department of Medicine  at Awali Hospital, Bahrain. He is the educational coordinator and  chairman of resuscitation  committee of the hospital. He is the regional coordinator  and examiner for  MRCP  exam for the Royal College of Physicians of Edinburgh. He is external examiner for Arabian Gulf Medical  University. He is also the immediate past chairman of Medical Advisory Committee. He has to his credit  numerous publications and he has presented his work in  different parts of the world. He is peer review author for some well respected Internation  journil.

Abstract

Diabetes is a growing problem globally despite all advances in its management strategy. In the last decade particularly there has been a plethora of newer anti diabetic medications that have been introduced in the market.

Recent trials and studies have shown promising results in terms of cardiovascular event reduction using some newer classes of anti-diabetic medications such as GLP1 agonist and SGLT2 Inhibitors.  There are now well-established guidelines on use of these medications in certain group of patients.  The pathophysiology   of how they work, and their potential benefit are now well understood. Despite clear recent guidelines, a significant proportion of patients with established or risk of CVD are not on appropriate anti-diabetic medications.

      It is therefore needed that practicing physicians are educated and made aware of the use of these medications. At the same time, they also need to be aware of any side effects and contraindications and therefore use them judiciously.  A wiser decision and choice of these agents should be made in partnership with the patient after they are adequately educated of the proposed new medication.